4521.T

Kaken Pharmaceutical Co., Ltd. [4521.T] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

4521.T Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

4521.T's dividend payments are well covered by cash flows with cash payout ratio of 66.5%.

4521.T has more than 36 years of cash runway (436 months)

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

Profit margins (0.11%) are lower than the previous year (0.13%)

Top 10 Correlated ETFs

4521.T

Top 10 Correlated Stocks

4521.T

In the News

4521.T Financial details

Company Rating

Strong Buy

Market Cap

137.49B

Income

8.45B

Revenue

73.9B

Book val./share

3657.83

Cash/share

1841.83

Dividend

150

Dividend %

4.09%

Employees

1.16K

Optionable

Shortable

Yes

Earnings

01 Aug 2023

P/E

16.63

Forward P/E

PEG

-4.6

P/S

1.86

P/B

P/C

1.99

P/FCF

Quick Ratio

3.63

Current Ratio

5.85

Debt / Equity

0.03

LT Debt / Equity

EPS (TTM)

221.66

EPS next Y

EPS next Q

EPS this Y

-27.62%

EPS next Y

EPS next 5Y

EPS last 5Y

-11.78%

Revenue last 5Y

-5.03%

Revenue Q/Q

0.71%

EPS Q/Q

4.19%

SMA20

-4.13%

SMA50

-3.29%

SMA100

-3.36%

Inst Own

Inst Trans

ROA

ROE

ROC

0.13%

Gross Margin

54%

Oper. Margin

26%

Profit Margin

11%

Payout

Shs Outstand

37.47M

Shs Float

33.71M

Target Price

52W Range

3485.0-4075.0

52W High

-9.89%

52W Low

+5.37%

RSI

52.49

Rel Volume

1.6

Avg Volume

82.71K

Volume

132.7K

Perf Week

4.91%

Perf Month

-1.69%

Perf Quarter

-6.45%

Perf Half Y

-4.87%

Beta

0.317601

Volatility

52.13%, 87.38%

Prev Close

1.46%

Price

3672

Change

1.07%

4521.T Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-03-31

Metric	2018-03-31	2019-03-31	2020-03-31	2021-03-31	2022-03-31
Revenue per share	2.43K	2.36K	2.28K	1.94K	2K
Net income per share	470.55	445.78	494.89	347.37	251.44
Operating cash flow per share	536.27	529.89	701.79	372.64	351.15
Free cash flow per share	489.62	476.53	645.53	313.4	265.39
Cash per share	1.3K	1.47K	1.87K	2K	1.96K
Book value per share	2.81K	3.04K	3.28K	3.53K	3.63K
Tangible book value per share	2.81K	3.04K	3.28K	3.53K	3.43K
Share holders equity per share	2.81K	3.04K	3.28K	3.53K	3.63K
Interest debt per share	96.15	97.61	98.8	100.21	101.82
Market cap	254.15B	204.15B	196.87B	167.29B	147.73B
Enterprise value	212.93B	161.07B	141B	107.43B	90.56B
P/E ratio	13.35	11.49	10.16	12.48	15.47
Price to sales ratio	2.58	2.17	2.21	2.23	1.94
POCF ratio	11.71	9.66	7.17	11.63	11.08
PFCF ratio	12.83	10.74	7.79	13.83	14.66
P/B Ratio	2.23	1.69	1.53	1.23	1.07
PTB ratio	2.23	1.69	1.53	1.23	1.07
EV to sales	2.16	1.71	1.58	1.43	1.19
Enterprise value over EBITDA	7.14	5.95	4.82	5.23	4.52
EV to operating cash flow	9.81	7.62	5.13	7.47	6.79
EV to free cash flow	10.75	8.48	5.58	8.88	8.98
Earnings yield	0.07	0.09	0.1	0.08	0.06
Free cash flow yield	0.08	0.09	0.13	0.07	0.07
Debt to equity	0.03	0.03	0.03	0.03	0.03
Debt to assets	0.03	0.02	0.02	0.02	0.02
Net debt to EBITDA	-1.38	-1.59	-1.91	-2.91	-2.85
Current ratio	3.35	3.76	5	5.34	5.81
Interest coverage	1.72K	1.45K	1.56K	1.05K	1K
Income quality	1.14	1.19	1.03	0.77	0.96
Dividend Yield	0.02	0.03	0.03	0.03	0.04
Payout ratio	0.32	0.34	0.3	0.43	0.6
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.08	0.11	0.07	0.09	0.11
Intangibles to total assets	0	0	0	0	0.05
Capex to operating cash flow	-0.09	-0.1	-0.08	-0.16	-0.24
Capex to revenue	-0.02	-0.02	-0.02	-0.03	-0.04
Capex to depreciation	-0.89	-0.99	-0.95	-0.99	-1.31
Stock based compensation to revenue	0	0	0	0	0
Graham number	5.46K	5.52K	6.05K	5.25K	4.53K
ROIC	0.38	0.34	0.63	0.46	0.31
Return on tangible assets	0.12	0.11	0.12	0.08	0.06
Graham Net	555.36	766.4	1.28K	1.5K	1.45K
Working capital	73.65B	76.15B	86.68B	92.39B	91.56B
Tangible asset value	113.87B	121.13B	128.05B	135.63B	130.09B
Net current asset value	66.51B	68.88B	78.93B	86.59B	83.76B
Invested capital	0.03	0.03	0.03	0.03	0.03
Average receivables	0	0	0	0	0
Average payables	11.03B	11.47B	9.22B	8.07B	7.14B
Average inventory	16.57B	15.19B	13B	13.74B	15.09B
Days sales outstanding	0	0	0	0	0
Days payables outstanding	105.05	97.01	72.71	90.25	62.08
Days of inventory on hand	143.32	124.05	115.6	162.79	158.68
Receivables turnover	0	0	0	0	0
Payables turnover	3.47	3.76	5.02	4.04	5.88
Inventory turnover	2.55	2.94	3.16	2.24	2.3
ROE	0.17	0.15	0.15	0.1	0.07
Capex per share	-46.65	-53.37	-56.26	-59.24	-85.76

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q3

Metric	2021-12-31	2022-03-31	2022-06-30	2022-09-30	2022-12-31
Revenue per share	525.22	478.39	475.02	486.11	489.56
Net income per share	91.99	-18.19	75.88	79.8	83.14
Operating cash flow per share	0	0	0	0	0
Free cash flow per share	0	0	0	0	0
Cash per share	1.75K	1.95K	1.92K	1.97K	1.84K
Book value per share	3.63K	3.6K	3.58K	3.65K	3.66K
Tangible book value per share	3.47K	3.4K	3.38K	3.45K	3.45K
Share holders equity per share	3.63K	3.6K	3.58K	3.65K	3.66K
Interest debt per share	100.61	100.63	100.61	100.61	100.61
Market cap	161.28B	149.02B	146.15B	146.15B	149.02B
Enterprise value	111.76B	91.84B	90B	89.23B	97.01B
P/E ratio	11.44	-53.45	12.57	11.95	11.7
Price to sales ratio	8.02	8.13	8.03	7.85	7.95
POCF ratio	0	0	0	0	0
PFCF ratio	0	0	0	0	0
P/B Ratio	1.16	1.08	1.06	1.05	1.06
PTB ratio	1.16	1.08	1.06	1.05	1.06
EV to sales	5.55	5.01	4.95	4.79	5.17
Enterprise value over EBITDA	22.24	28.48	20.76	21.1	21.92
EV to operating cash flow	0	0	0	0	0
EV to free cash flow	0	0	0	0	0
Earnings yield	0.02	0	0.02	0.02	0.02
Free cash flow yield	0	0	0	0	0
Debt to equity	0.03	0.03	0.03	0.03	0.03
Debt to assets	0.02	0.02	0.02	0.02	0.02
Net debt to EBITDA	-9.85	-17.73	-12.95	-13.46	-11.75
Current ratio	5.05	5.81	5.7	5.88	5.85
Interest coverage	1.21K	1.39K	1.01K	1.04K	1.05K
Income quality	0	0	0	0	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.1	0.13	0.11	0.12	0.11
Intangibles to total assets	0.04	0.05	0.05	0.05	0.05
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	2.74K	1.21K	2.47K	2.56K	2.62K
ROIC	0.06	0.23	0.08	0.08	0.06
Return on tangible assets	0.02	0	0.02	0.02	0.02
Graham Net	1.24K	1.44K	1.42K	1.48K	1.35K
Working capital	89.45B	91.56B	91.32B	93.79B	94.08B
Tangible asset value	133.09B	130.09B	129.58B	132.09B	132.23B
Net current asset value	83.53B	83.76B	83.51B	86.1B	86.43B
Invested capital	0.03	0.03	0.03	0.03	0.03
Average receivables	0	0	0	0	0
Average payables	7.48B	6.87B	6.21B	6.61B	7.1B
Average inventory	17.05B	15.95B	15.35B	15.94B	16.49B
Days sales outstanding	0	0	0	0	0
Days payables outstanding	77.97	60.15	72.34	72.39	79.24
Days of inventory on hand	167.31	153.75	173.47	175.7	176.49
Receivables turnover	0	0	0	0	0
Payables turnover	1.15	1.5	1.24	1.24	1.14
Inventory turnover	0.54	0.59	0.52	0.51	0.51
ROE	0.03	-0.01	0.02	0.02	0.02
Capex per share	0	0	0	0	0

4521.T Dividend History

4521.T Frequently Asked Questions

What is Kaken Pharmaceutical Co., Ltd. stock symbol ?

Kaken Pharmaceutical Co., Ltd. is a JP stock and trading under the symbol 4521.T

What is Kaken Pharmaceutical Co., Ltd. stock quote today ?

Kaken Pharmaceutical Co., Ltd. stock price is $3672 today.

Is Kaken Pharmaceutical Co., Ltd. stock public?

Yes, Kaken Pharmaceutical Co., Ltd. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 82.71K
Market Capitalization 137.49B
Employee 1.16K
CEO Mr. Hiroyuki Horiuchi
Headquarters Tokyo,JP
IPO Date 2001-01-01
Website https://www.kaken.co.jp

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.